OncoMatch/Clinical Trials/NCT06287775
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Is NCT06287775 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Atezolizumab and Durvalumab for extensive stage lung small cell carcinoma.
Treatment: Atezolizumab · Durvalumab · Iadademstat — This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV (AJCC v8)
Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (platinum, etoposide) — first-line, in combination with immunotherapy
treated with platinum etoposide chemotherapy plus either atezolizumab or durvalumab immunotherapy for at least 4 cycles, and no more than 6 cycles, with either a radiographic response or stable disease
Must have received: anti-PD-L1 therapy (atezolizumab, durvalumab) — first-line, in combination with platinum-etoposide
treated with platinum etoposide chemotherapy plus either atezolizumab or durvalumab immunotherapy for at least 4 cycles, and no more than 6 cycles, with either a radiographic response or stable disease
Cannot have received: maintenance immune checkpoint inhibitor therapy
Patients who receive maintenance ICI therapy prior to cycle 1, day 1
Lab requirements
Blood counts
Leukocytes ≥ 2,000/mcL; Lymphocyte count ≥ 500/mcL; Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcL
Kidney function
Glomerular filtration rate (GFR) ≥ 45 mL/min
Liver function
Total bilirubin ≤ 1.5 institutional ULN; AST/ALT ≤ 3 × institutional ULN unless liver metastases are present, in which case ≤ 5 × ULN; Albumin ≥ 3 g/dL
Leukocytes ≥ 2,000/mcL; Lymphocyte count ≥ 500/mcL; Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcL; Albumin ≥ 3 g/dL; Total bilirubin ≤ 1.5 institutional ULN; AST/ALT ≤ 3 × institutional ULN unless liver metastases are present, in which case ≤ 5 × ULN; Glomerular filtration rate (GFR) ≥ 45 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- UC San Diego Moores Cancer Center · La Jolla, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- Smilow Cancer Hospital Care Center at Saint Francis · Hartford, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify